Health
Antibody improves progression-free survival in patients with advanced prostate cancer – News-Medical.Net
An antibody for treating advanced prostate cancer improves progression-free survival in patients with metastasised, castration-resistant prostate cancer.
Reviewed by Emily Henderson, B.Sc.Sep 29 2020
An antibody for treating advanced prostate cancer improves progression-free survival in patients with metastasized, castration-resistant prostate cancer.
This is the finding of the long-term analyses of an international phase 3 clinical trial, recently published in the leading journal “European Urology”. The study showed that overall survival was 2 – 3 times higher than in the placebo arm.
Ipilimumab is a humanized monoclonal IgG1 antibody that is…
-
Noosa News21 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
Noosa News20 hours agoDefence investigation finds Taipan pilot’s actions possibly prevented further fatalities in crash
-
Noosa News19 hours agoNo matter what happens in his Origin debut, history beckons for rookie maroon Robert Toia
-
General17 hours agoDairy farmers devastated by floods across parts of New South Wales